Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells
暂无分享,去创建一个
S. Kesari | S. Chien | R. Mukthavaram | Pengfei Jiang | S. Pingle | N. Nomura | D. Teng | Peiying Zhang | Fang Guo | Rajesh Mukthavaram | Natsuko Nomura
[1] Y. Tu,et al. Genetic Characteristics of Glioblastoma: Clinical Implications of Heterogeneity , 2015 .
[2] D. Kamp,et al. miR-5100 promotes tumor growth in lung cancer by targeting Rab6. , 2015, Cancer letters.
[3] T. Ohm,et al. Geranylgeranyl pyrophosphate is crucial for neuronal survival but has no special role in Purkinje cell degeneration in Niemann Pick type C1 disease , 2015, Journal of neurochemistry.
[4] S. Pastorino,et al. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells , 2014, British Journal of Cancer.
[5] Panagiotis Karras,et al. RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway. , 2014, Cancer cell.
[6] Q. Ni,et al. High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival , 2014, Medical Oncology.
[7] Taher Abbasi,et al. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs , 2014, Journal of Translational Medicine.
[8] J. Carles,et al. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study , 2013, British Journal of Cancer.
[9] Alireza Khoshnevisan,et al. A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care , 2013, Oncotarget.
[10] R. Goody,et al. Development of selective, potent RabGGTase inhibitors. , 2012, Journal of medicinal chemistry.
[11] Hiroshi Kobayashi,et al. Zoledronic Acid Produces Antitumor Effects on Mesothelioma Through Apoptosis and S-Phase Arrest in p53-Independent and Ras prenylation-Independent Manners , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] R. Goody,et al. Psoromic acid is a selective and covalent Rab-prenylation inhibitor targeting autoinhibited RabGGTase. , 2012, Journal of the American Chemical Society.
[13] J. Cui,et al. Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma. , 2012, World journal of gastroenterology.
[14] E. Oldfield,et al. Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity , 2012, Proceedings of the National Academy of Sciences.
[15] M. Pilon,et al. The mevalonate pathway in C. Elegans , 2011, Lipids in Health and Disease.
[16] S. Sebti,et al. Targeting protein prenylation for cancer therapy , 2011, Nature Reviews Cancer.
[17] W. Gregory,et al. Breast-cancer adjuvant therapy with zoledronic acid. , 2011, The New England journal of medicine.
[18] R. Coleman,et al. Anticancer evidence for zoledronic acid across the cancer continuum. , 2011, Critical reviews in oncology/hematology.
[19] M. Scheper,et al. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers , 2011, Journal of carcinogenesis.
[20] C. Agrati,et al. Zoledronic Acid Enhances Vδ2 T-Lymphocyte Antitumor Response to Human Glioma Cell Lines , 2011, International journal of immunopathology and pharmacology.
[21] A. Bhangu-Uhlmann. The mevalonate pathway , 2011 .
[22] I. Holen,et al. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer , 2010, Breast Cancer Research.
[23] P. Boutros,et al. Dysregulation of the mevalonate pathway promotes transformation , 2010, Proceedings of the National Academy of Sciences.
[24] K. Nackaerts,et al. Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] Ting-Kai Chang,et al. Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. , 2009, Journal of the American Chemical Society.
[26] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[27] Z. Shao,et al. Enhanced Expression of Rab27A Gene by Breast Cancer Cells Promoting Invasiveness and the Metastasis Potential by Secretion of Insulin-Like Growth Factor-II , 2008, Molecular Cancer Research.
[28] M. Caraglia,et al. Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients , 2007, Clinical Cancer Research.
[29] E. Oldfield,et al. Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases , 2007, Proceedings of the National Academy of Sciences.
[30] G. A. van der Marel,et al. Inhibitors of protein: geranylgeranyl transferases. , 2006, Current medicinal chemistry.
[31] S. Knapp,et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[32] M. Thoulouzan,et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells , 2006, BMC Cancer.
[33] Brad E. Pfeiffer,et al. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[34] P. Casey,et al. Conversion of protein farnesyltransferase to a geranylgeranyltransferase. , 2006, Biochemistry.
[35] J. Hohneker,et al. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. , 2003, Seminars in oncology.
[36] M. Glatt,et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). , 2002, Journal of medicinal chemistry.
[37] H. Goodson,et al. Late endosome motility depends on lipids via the small GTPase Rab7 , 2002, The EMBO journal.
[38] B. Roe,et al. The gene for the muted (mu) mouse, a model for Hermansky-Pudlak syndrome, defines a novel protein which regulates vesicle trafficking. , 2002, Human molecular genetics.
[39] K. Colston,et al. The potential role of bisphosphonates in prostate cancer , 2002, Prostate Cancer and Prostatic Diseases.
[40] Harald Stenmark,et al. The Rab GTPase family , 2001, Genome Biology.
[41] F. Singer,et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. , 2001, Cancer research.
[42] L. Collinson,et al. Rab27a Regulates the Peripheral Distribution of Melanosomes in Melanocytes , 2001, Journal of Cell Biology.
[43] C. Poulter,et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. , 2001, The Journal of pharmacology and experimental therapeutics.
[44] S. Kingsmore,et al. Rab geranylgeranyl transferase alpha mutation in the gunmetal mouse reduces Rab prenylation and platelet synthesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[45] B. Kasiske,et al. Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis. , 1999, Kidney international. Supplement.
[46] B. Goud,et al. Interaction of a Golgi-associated kinesin-like protein with Rab6. , 1998, Science.
[47] P. Casey,et al. Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.
[48] Y. Masuda,et al. Geranylgeraniol is a potent inducer of apoptosis in tumor cells. , 1995, Journal of biochemistry.
[49] K. Jaeggi,et al. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[50] P. Casey,et al. Protein farnesyltransferase and geranylgeranyltransferase share a common α subunit , 1991, Cell.
[51] P. Casey,et al. Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit. , 1991, Cell.